0001178913-20-000593.txt : 20200219 0001178913-20-000593.hdr.sgml : 20200219 20200219080013 ACCESSION NUMBER: 0001178913-20-000593 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200219 FILED AS OF DATE: 20200219 DATE AS OF CHANGE: 20200219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Entera Bio Ltd. CENTRAL INDEX KEY: 0001638097 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38556 FILM NUMBER: 20627440 BUSINESS ADDRESS: STREET 1: KIRYAT HADASSAH, MINRAV BUILDING STREET 2: FIFTH FLOOR CITY: JERUSALEM STATE: L3 ZIP: 9112002 BUSINESS PHONE: 972-2-532-7151 MAIL ADDRESS: STREET 1: KIRYAT HADASSAH, MINRAV BUILDING STREET 2: FIFTH FLOOR CITY: JERUSALEM STATE: L3 ZIP: 9112002 6-K 1 zk2024074.htm 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2020

Commission file number: 001- 38556

ENTERA BIO LTD.
(Translation of registrant's name into English)

Kiryat Hadassah
Minrav Building – Fifth Floor
Jerusalem, Israel
 (Address of principal executive office)
_____________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

CONTENTS

Results of the Extraordinary General Meeting of the Shareholders

On February 18, 2020, Entera Bio Ltd. (the “Company”) held an extraordinary general meeting of shareholders (the “Meeting”). At the Meeting, the Company’s shareholders voted on three proposals, each of which is described in more detail in the Company’s proxy statement for the Meeting attached as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K the Company filed with the Securities and Exchange Commission on January 14, 2020 (the “Proxy Statement”).

Based on the results and the majority requirements under the Israeli Companies Law 5759-1999 (the “Companies Law”) and the Company’s Articles of Association, the shareholders of the Company duly approved the following resolutions:

(1)
To ratify and approve the terms of compensation of Mr. Jonathan Lieber, our U.S.-based Chief Financial Officer, for a period commencing as of November 21, 2019, and onward (Proposal 1);

(2)
To ratify and approve the grant of 33,638 options to Mr. Sean Ellis, a non-executive director of the Company, as of November 18, 2019 (Proposal 2); and

(3)
To approve a private placement with D.N.A Biomedical Solutions Ltd., or DNA, our principal shareholder (Proposal 3).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
Entera Bio Ltd.
(Registrant)

  
 
By:
/s/ Mr. Adam Gridley
  
   
Name: Adam Gridley
  
   
Title: Chief Executive Officer
  

Date: February 19, 2020